Article
Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.
Pharmacological research - 1 Nov 2016
Puszkiel Alicja, White-Koning Mélanie, Dupin Nicolas, Kramkimel Nora, Thomas-Schoemann Audrey, Noé Gaëlle, Chapuis Nicolas, Vidal Michel, Goldwasser François, Chatelut Etienne, Blanchet Benoit
Abstract excerpt
The therapeutic response to vemurafenib, a BRAF serine-threonine kinase inhibitor, exhibits large variations between patients. Evaluation of factors predicting the clinical efficacy of vemurafenib may help to identify patients at high risk of non-response in the early phase of treatment. The aim of this study was to analyze the pharmacokinetics of vemurafenib by a population approach and to evaluate the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.